Treatment strategies for hot flushes

Bibliography

• Williams RE, Kalilani L, Dibenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11(1):32-43
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10(3):197-214
   PubMed Web of Science ®Google Scholar
• Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause 2005;12(2):156-9
   PubMed Web of Science ®Google Scholar
• Stearns V. Clinical update: new treatments for hot flushes. Lancet 2007;369(9579):2062-4
   PubMed Web of Science ®Google Scholar
• Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 2005;14(4):435-48
   PubMed Web of Science ®Google Scholar
• Randolph JF Jr, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005;90(11):6106-12
   PubMed Web of Science ®Google Scholar
• Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007;10(6):247-57
   PubMed Web of Science ®Google Scholar
• Nelson HD. Menopause. Lancet 2008;371(9614):760-70
   PubMed Web of Science ®Google Scholar
• Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004(4):CD002978
   Google Scholar
• Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92(6):982-8
   PubMed Web of Science ®Google Scholar
• Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75(6):1065-79
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7(5):310-17
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Lenihan JP, Mcdermott M, et al. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95(5):726-31
   PubMed Web of Science ®Google Scholar
• Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 2000;3(3):176-82
   PubMedGoogle Scholar
• Simon JA, Snabes MC. Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen. Expert Opin Investig Drugs 2007;16(12):2005-20
   PubMed Web of Science ®Google Scholar
• Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 2007;57(1):81-4
   PubMed Web of Science ®Google Scholar
• Carranza-Lira S, Gooch AL, Velasco-Diaz G, et al. Low and ultra low-dose estrogen therapy for climacteric symptom control–preliminary report. Int J Fertil Womens Med 2006;51(4):171-5
   PubMed Web of Science ®Google Scholar
• De Franciscis P, Cobellis L, Fornaro F, et al. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet 2007;98(2):138-42
   PubMed Web of Science ®Google Scholar
• Panay N, Ylikorkala O, Archer DF, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10(2):120-31
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110(4):771-9
   PubMed Web of Science ®Google Scholar
• Rowan JP, Simon JA, Speroff L, Ellman H. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin Ther 2006;28(6):921-32
   PubMed Web of Science ®Google Scholar
• Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40(4):561-82
   PubMed Web of Science ®Google Scholar
• Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Saf 1993;9(5):365-79
   PubMed Web of Science ®Google Scholar
• Good WR, John VA, Ramirez M, Higgins JE. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms. Alora Study Group. Clin Ther 1996;18(6):1093-105
   PubMed Web of Science ®Google Scholar
• Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999;181(1):71-9
   PubMed Web of Science ®Google Scholar
• Bacchi-Modena A, Bolis P, Campagnoli C, et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas 1997;27(3):285-92
   PubMed Web of Science ®Google Scholar
• Speroff L, Whitcomb RW, Kempfert NJ, et al. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88(4 Pt 1):587-92
   PubMed Web of Science ®Google Scholar
• Rovati LC, Setnikar I, Genazzani AR. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group. Gynecol Endocrinol 2000;14(4):282-91
   PubMed Web of Science ®Google Scholar
• de Vrijer B, Snijders MP, Troostwijk AL, et al. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women. Maturitas 2000;34(1):47-55
   PubMed Web of Science ®Google Scholar
• Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13(2):99-107
   PubMed Web of Science ®Google Scholar
• Vartiainen J, Wahlstrom T, Nilsson CG. Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 1993;17(2):129-37
   PubMed Web of Science ®Google Scholar
• Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15(4 Pt 1):584-602
   PubMed Web of Science ®Google Scholar
• Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002;13(6):883-8
   PubMed Web of Science ®Google Scholar
• Prior JC, Nielsen JD, Hitchcock CL, et al. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond) 2007;112(10):517-25
   PubMed Web of Science ®Google Scholar
• Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94(2):225-8
   PubMed Web of Science ®Google Scholar
• Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6(6):2311-22
   PubMed Web of Science ®Google Scholar
• Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992;75(2):558-63
   PubMed Web of Science ®Google Scholar
• Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990;70(4):920-4
   PubMed Web of Science ®Google Scholar
• Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. Int J Fertil Womens Med 2006;51(2):64-9
   PubMed Web of Science ®Google Scholar
• Vasomotor symptoms. Obstet Gynecol 2004;104(4 Suppl):106S-17S
   PubMedGoogle Scholar
• Haney AF, Wild RA. Options for hormone therapy in women who have had a hysterectomy. Menopause 2007;14(3 Pt 2):592-7; quiz 8-9
   PubMed Web of Science ®Google Scholar
• Haimov-kochman R, Barak-glantz E, Ein-mor E, et al. Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective cohort study. Hum Reprod 2006;21(9):2450-4
   PubMed Web of Science ®Google Scholar
• Aslan E, Bagis T, Kilicdag EB, et al. How best is to discontinue postmenopausal hormone therapy: immediate or tapered? Maturitas 2007;56(1):78-83
   PubMed Web of Science ®Google Scholar
• Haimov-Kochman R, Barak-Glantz E, Arbel R, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause 2006;13(3):370-6
   PubMed Web of Science ®Google Scholar
• Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118(Suppl 12B):163-5
   PubMed Web of Science ®Google Scholar
• Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006;53(3):356-61
   PubMed Web of Science ®Google Scholar
• Liu JH. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005;118(Suppl 12B):88-92
   PubMedGoogle Scholar
• Hammar ML, van de Weijer P, Franke HR, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114(12):1522-9
   PubMed Web of Science ®Google Scholar
• Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13(6):917-25
   PubMed Web of Science ®Google Scholar
• Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109(10):1109-14
   PubMed Web of Science ®Google Scholar
• Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002;87(1):16-23
   PubMed Web of Science ®Google Scholar
• Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000;36(3):155-64
   PubMed Web of Science ®Google Scholar
• Umland EM. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm 2008;14(3 Suppl):14-9
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295(17):2057-71
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual subject pooled analysis [abstract 9537]. J Clin Oncol 2008;26
   Google Scholar
• Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289(21):2827-34
   PubMed Web of Science ®Google Scholar
• Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23(28):6919-30
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356(9247):2059-63
   PubMed Web of Science ®Google Scholar
• Soares CN, Joffe H, Viguera AC, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med 2008;121(2):159-62 e1
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20(6):1578-83
   PubMed Web of Science ®Google Scholar
• Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13(5):780-6
   PubMed Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318(2):657-65
   PubMed Web of Science ®Google Scholar
• Barton DL, Loprinzi CL, Atherton P, et al. Phase II evaluation of desipramine for the treatment of hot flashes. Support Cancer Ther 2007;4(4):219-24
   PubMedGoogle Scholar
• Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111(1):77-87
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Stearns V, Barton D. Centrally active nonhormonal hot flash therapies. Am J Med 2005;118(Suppl 12B):118-23
   PubMedGoogle Scholar
• Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007;25(3):308-12
   PubMed Web of Science ®Google Scholar
• Fugate SE, Church CO. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother 2004;38(9):1482-99
   PubMed Web of Science ®Google Scholar
• Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. J Br Menopause Soc 2006;12(1):7-11
   PubMedGoogle Scholar
• Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196(2):97-106
   PubMed Web of Science ®Google Scholar
• Ladd CO, Newport DJ, Ragan KA, et al. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22(2):94-7
   PubMed Web of Science ®Google Scholar
• Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 2006;5(2):83-7
   PubMedGoogle Scholar
• Phillips BB, Digmann RR, Beck MG. Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms. Ann Pharmacother 2006;40(2):323-7
   PubMed Web of Science ®Google Scholar
• Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15(2):310-8
   PubMed Web of Science ®Google Scholar
• Daley A, MacArthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD006108
   Google Scholar
• American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 2006;12(3):315-37
   PubMedGoogle Scholar
• Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11(1):11-33
   PubMed Web of Science ®Google Scholar
• Greendale GA, Gold EB. Lifestyle factors: are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy? Am J Med 2005;118(Suppl 12B):148-54
   PubMed Web of Science ®Google Scholar
• Shrader SP, Ragucci KR. Life after the women's health initiative: evaluation of postmenopausal symptoms and use of alternative therapies after discontinuation of hormone therapy. Pharmacotherapy 2006;26(10):1403-9
   PubMed Web of Science ®Google Scholar
• Lasley BL, Santoro N, Randolf JF, et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab 2002;87(8):3760-7
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24(2):152-82
   PubMed Web of Science ®Google Scholar
• Bardia A, Thompson S, Atherton PJ, et al. Pilot evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther 2006;3(4):240-6
   PubMedGoogle Scholar
• Notelovitz M. Hot flashes and androgens: a biological rationale for clinical practice. Mayo Clin Proc 2004;79(4 Suppl):S8-13
   Google Scholar
• Stomati M, Monteleone P, Casarosa E, et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 2000;14(5):342-63
   PubMed Web of Science ®Google Scholar
• Simon J, Klaiber E, Wiita B, et al. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999 Summer;6(2):138-46
   PubMed Web of Science ®Google Scholar
• Khorram O. Potential therapeutic effects of prescribed and over-the-counter androgens in women. Clin Obstet Gynecol 2001;44(4):880-92
   PubMed Web of Science ®Google Scholar
• Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78(6):1360-7
   PubMed Web of Science ®Google Scholar
• Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84(11):3896-902
   PubMed Web of Science ®Google Scholar
• Lethaby AE, Brown J, Marjoribanks J, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD001395
   Google Scholar
• Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9(5):329-34
   PubMed Web of Science ®Google Scholar
• Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000;7(4):236-42
   PubMed Web of Science ®Google Scholar
• Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18(5):1068-74
   PubMed Web of Science ®Google Scholar
• Han KK, Soares JM Jr, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002;99(3):389-94
   PubMed Web of Science ®Google Scholar
• MacGregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005;41(5):708-14
   PubMed Web of Science ®Google Scholar
• Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101(6):1213-20
   PubMed Web of Science ®Google Scholar
• Penotti M, Fabio E, Modena AB, et al. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril 2003;79(5):1112-7
   PubMed Web of Science ®Google Scholar
• Lewis JE, Nickell LA, Thompson LU, et al. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 2006;13(4):631-42
   PubMed Web of Science ®Google Scholar
• Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008;15(1):125-32
   PubMed Web of Science ®Google Scholar
• D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause 2007;14(4):648-55
   PubMed Web of Science ®Google Scholar
• Nahas EA, Nahas-Neto J, Orsatti FL, et al. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007;58(3):249-58
   PubMed Web of Science ®Google Scholar
• Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145(12):869-79
   PubMed Web of Science ®Google Scholar
• Reed SD, Newton KM, LaCroix AZ, et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15(1):51-8
   PubMed Web of Science ®Google Scholar
• Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006;24(18):2836-41
   PubMed Web of Science ®Google Scholar
• Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas 2006;55(Suppl 1):S3-13
   Google Scholar
• Treatment of menopausal vasomotor symptoms. Med Lett Drugs Ther 2004;47(1197-1198):98-9
   PubMed Web of Science ®Google Scholar
• NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consens State Sci Statements 2005;22(1):1-38
   Google Scholar
• Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstetrics Gynecol 2005;105(1):161-6
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Perez PA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12(1):18-26
   PubMed Web of Science ®Google Scholar
• Reddy SY, Warner H, Guttuso T Jr, et al. Gabapetin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108(1):41-8
   PubMed Web of Science ®Google Scholar